The U.S. Food and Drug Administration (FDA) has issued a warning letter to a company that sells products with fraudulent claims to prevent, treat, mitigate, diagnose, or cure COVID-19.
On November 1, the FDA issued Alternative Health Distribution LLC d/b/a CannaAid, which markets cannabinoid products, including cannabidiol (CBD) products, to mitigate, prevent, treat, diagnose, or cure COVID-19. The website claimed that “Recent analyses from numerous preliminary in vitro and animal studies have shown that cannabinoids in hemp, specifically CBD, can significantly reduce COVID-19’s ability to infect new cells – limiting inflammation in the lungs and possibly improving a patients’ quality of life during severe COVID-19 infection.”
The FDA’s letter stated that these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and are misbranded drugs under section 502 of the FD&C Act. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act.
The FDA has only approved on CBD prescription drug in the U.S., and it is illegal under U.S. law to market CBD as a food ingredient or dietary supplement. Read the November 1 letter here.
Read Aimed Alliance’s Cannabinoids Fact Sheet here.
Last Updated on November 30, 2022 by Aimed Alliance
